Hims & Hers Health (HIMS.US) rose over 5% to a new record high

Hims & Hers Health (HIMS.US) rose over 5% on Wednesday, setting a new record high of US$32.23. On Monday, Hunterbrook Media, an institution that "targets short-seller Citron", released a report stating that Trump nominated Marty Makary as the head of the US Food and Drug Administration (FDA), and Hims & Hers may benefit greatly from this nomination, as Makary is a senior executive of Sesame Inc., which is a startup that sells the same combination GLP-1 weight loss drug as Hims & Hers.